Objective To study the value of MP-DNA in the early diagnosis of pneumonia by analyzing the result of MP-DNA in bronchoalveolar lavage fluid(BALF) and MP-IgM antibodies in serum.Methods 103 hospitalized children were detected for MP-DNA in BALF(positive:DNA copies ＞ 102/ml) and MP-IgM antibodies in serum.Results The MP-DNA positive in BALF and the MP-IgM positive in serum in children with pneumoina were significantly higher than those in children with foreign body in bronchus (x2 =13.00,4.11,all P ＜ 0.05).33.01％ of 103 children was MP-DNA positive,19.43％ of 103 children was MP-IgM positive.The MP-DNA positive in BALF was significantly higher than the MP-IgM positive in serum(x2 =4.92,P ＜0.05).Conclusion The samples of MP-DNA in BALF were collected more difficulty than the samples of MP-IgM in serum,but the detection of MP-DNA can avoid the false negative,which may be of value in the diagnosis and therapy of MPP.

Lung cancer is one of the most common malignancies with the highest incidence rate and mortality rate worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85%. Only 5% NSCLC patients are anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, but the prognosis of these patients is poor, and treatment is urgent. Ensartinib (X-396), a next-generation ALK tyrosine kinase inhibitor (ALK-TKI), has shown greater potency on inhibiting ALK activity and controlling brain metastases than crizotinib, which is indicated for the treatment of crizotinib-resistant, ALK-positive NSCLC patients. Several phase I to III clinical trials included both healthy volunteers and NSCLC patients have been conducted both in China and abroad. In this review, we briefly summarized the results of these trials, and preliminary efficacy, safety, pharmacology and pharmacokinetics/pharmacodynamics of ensartinib were discussed.